The CHMP’s positive opinion of Imfinzi + CT followed by Lynparza & Imfinzi (pMMR disease) or Imfinzi alone (dMMR disease) was supported by a prespecified exploratory subgroup analysis from P-III (DUO-E) study. Review of further submissions for the same is underway in Japan & other regions
The P-III (DUO-E) study assessed 1L Imfinzi + CT (carboplatin & paclitaxel) followed by either Imfinzi alone or Imfinzi + Lynparza as maintenance treatment vs CT alone to treat newly diagnosed advanced/recurrent endometrial cancer patients (n=699)
The analysis demonstrated PFS of 43% (median: 15mos. vs 9.7mos.) in pMMR patients and 58% (median not attained vs 7mos.) in dMMR patients
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
